TITLE

Stroke drug earns phase-3 trial

AUTHOR(S)
Walters, Kath
PUB. DATE
February 2007
SOURCE
BRW;2/8/2007, Vol. 29 Issue 5, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that biotechnology company Neuren Pharmaceuticals Ltd. has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase three drug trial of Glypromate, which is designed to prevent cognitive impairment in heart-surgery patients. If the trial is successful, it can apply for FDA approval to begin selling the drug. The trial, which cost $10 million and involve a total of 520 patients, is expected to take 18 months.
ACCESSION #
24625884

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics